Atea Pharmaceuticals (AVIR) Preferred Stock Liabilities (2019 - 2020)
Atea Pharmaceuticals (AVIR) posted quarterly Preferred Stock Liabilities of $175.7 million for Q3 2020, up 154.28% year-over-year from $69.1 million in Q4 2019, and little changed quarter-over-quarter from $175.7 million in Q2 2020.
Powered by 
Analysis
Atea Pharmaceuticals (AVIR) Preferred Stock Liabilities (2019 - 2020) Analysis & Trends
Atea Pharmaceuticals' Preferred Stock Liabilities history runs 2 years deep, the most recent figure standing at $175.7 million for Q3 2020.
- In Q3 2020, Preferred Stock Liabilities rose 154.28% year-over-year to $175.7 million; the TTM figure through Sep 2020 stood at $175.7 million (up 154.28% YoY), while the FY2019 annual figure was $69.1 million, changed 0.0% from the prior year.
- Preferred Stock Liabilities for Q3 2020 stood at $175.7 million, roughly flat from $175.7 million in the prior quarter.
- The five-year high for Preferred Stock Liabilities was $175.7 million in Q2 2020, with the low at $69.1 million in Q3 2019.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Atea Pharmaceuticals | 467.50 Mn | 467.50 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Sep 30, 2020 | 175.75 Mn |
| Jun 30, 2020 | 175.75 Mn |
| Mar 31, 2020 | 69.11 Mn |
| Dec 31, 2019 | 69.11 Mn |
| Sep 30, 2019 | 69.11 Mn |